In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19.
For this episode, we speak to Philip Robinson, chair of the steering committee of the COVID-19 Global Rheumatology Alliance, about TNF inhibitors. He discusses why these agents should be prioritized for evaluation in randomized controlled trials, what the data show, and which patients may be most likely to benefit (16:39).
Listen below or subscribe to this Podcast on:
Google Podcasts | Apple Podcasts | Spotify | Stitcher | TuneIn
About the speaker